SEC Form 4 · accession 0001144204-15-063926
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Gill
Officer — President and CEO · Director
Period of report
Nov 5, 2015
Accepted (ET)
Nov 9, 2015 · 6:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1,F2 | Nov 5, 2015 | A | 612,244 | $0.00 | A | 612,244 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a grant of shares of restricted stock vesting upon the earliest to occur of (a) a change in control of the Issuer, (b) each of three predetermined milestones, or (c) the termination of Mr. Gill's employment for any reason other than (1) a termination for cause or (2) a voluntary resignation.
- F2On November 5, 2015, the date of grant, the closing price of the Issuer's common stock on the NYSE MKT was $1.80 per share.